Advanced Search

 

Study ID Status Title Patient Level Data
218352/048 Completed Immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age.
218352/049 Completed Immunization study to determine the reactogenicity and safety of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age
218352/051 Completed Open immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2002/2003 in persons as of 18 years of age
218352/052 Completed Open, multicentric, randomized, compared vaccination study to evaluate non-inferiority of influenza-vaccine Influsplit SSW®/Fluarix™ 2002/2003 versus the adjuvanted influenza-vaccines Fluad® 2002/2003 and Inflexal V® 2002/2003 concerning immunogenicity and reactogenicity in subjects aged over 60 years
218352/053 Completed Comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18 years
218352/054 Completed Study to monitor the safety and reactogenicity of GlaxoSmithKline Biologicals’ influenza split vaccine FLUARIX™ administered according to the Prescribing Information in Korean subjects aged more than 6 months of age at the time of vaccination Study Listed on ClinicalStudyDataRequest.com
219550/012 Completed Open, multicentric, post marketing surveillance study of GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (TYPHERIX™) injected in healthy children and adults according to the Indian prescribing information.Typherix™: GlaxoSmithKline Biologicals’ Vi polysaccharide typhoid vaccine (Typh)
223030/059 Completed A Multicentre, Randomised, Double-Blind, Study of Idoxifene 40mg/dayversus Tamoxifene 20mg/day as First-Line Hormonal Therapy in Postmenopausal Women with Metastatic Breast Cancer
223030/150 Completed A combined report for protocols SB223030/015 and SB223030/016: a randomized, double-blind, placebo-controlled trial of the effect of idoxifene in the prevention of bone loss in early postmenopausal women and a randomized, double-blind, placebo-controlled trial of the effect of idoxifene in the p ...
223412/068 Completed An Eight-week, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety of talnetant in subjects with irritable bowel syndrome
227855/001 Completed Phase I study in elderly population aged over 65 years in order to evaluate reactogenicity and immunogenicity of GlaxoSmithKline Biologicals' experimental Influenza vaccine or a Whole virus vaccine. For both immunogenicity and safety evaluations, the commercial inactivated split vaccine Fluarix will be used as reference Study Listed on ClinicalStudyDataRequest.com
249553/004 Completed A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection
25000/233 Completed A Comparison of the Efficacy and Safety of Augmentin 875/125 mg po q 12 hrs and Augmentin 500/125 mg po q 8 hrs in the Treatment of Pyelonephritis and Complicated Urinary Tract Infections. A Double-Blind, Multi-Center, Comparative Study.
25000/234 Completed A Comparison of the Efficacy and Safety of Augmentin 875/125 mg po q 12 hours versus Augmentin 500/125 mg po q 8 hours in the Treatment of Lower Respiratory Tract Infections.
25000/311 Completed A comparison of the efficacy, safety and tolerability of Augmentin 60/15 mg/kg/day (4:1 ratio) given po in three divided doses versus Augmentin™ 70/10 mg/kg/day (7:1 ratio) given po in two divided doses in the treatment of children with acute otitis media….
25000/314 Completed A Comparison of the Efficacy and Safety of Augmentin 45/6.4 mg/kg/day in Divided Doses q12h for 10 days, Augmentin 45/6.4 mg/kg/day in Divided Doses q12h for 5 days, and Augmentin 40/10 mg/kg/day in Divided Doses q8h for 10 days in the Treatment of Acute Otitis Media in Children.
25000/325 Completed A comparison of the efficacy, safety and tolerability of Augmentin tid 20/5 mg/kg/day po versus Augmentin bid 25/3.6 mg/kg/day po in the treatment of acute bacterial lower respiratory tract infections in children.
25000/330 Completed A comparison of the efficacy, safety and tolerability of Augmentin 30/7.5 mg/kg/day po given in three divided doses (4:1 ratio) versus Augmentin 35/5 mg/kg/day po given in two divided doses (7:1 ratio) in the treatment of children with recurrent tonsillitis.
25000/382 Completed A parallel group study to estimate the steady state pharmacokinetics of amoxicillin and clavulanate in paediatric patients in the age range 1 month to 12 years administered Augmentin® 45/6.4 mg/kg/day (twice daily) or 40/10 mg/kg/day (three times daily) orally.
25000/446 Completed Comparison of Amoxicillin Concentrations in Plasma and Middle Ear Fluid Following Administration of Augmentin 45/3.2 mg/kg to Pediatric Patients with Acute Otitis Media.
25000/447 Completed A Comparison of the Safety and Efficacy of q 12 hrs Augmentin-90/6.4 mg/kg/day and q 12 hrs Augmentin-45/6.4 mg/kg/day in the Treatment of Acute Otitis Media in Children: A Randomized Double-Blind, Multicenter, Comparative Study.
25000/536 Completed An Open-Label Study to Demonstrate Bacteriological Efficacy of Augmentin ES in the Treatment of Acute Otitis Media Due to S. pneumoniae.
25000/541 Completed The Effect of Antimicrobial Therapy for Otitis Media on Pneumococcal Carriage and Antibiotic Resistance Study Listed on ClinicalStudyDataRequest.com
25000/542 Completed A pharmacokinetic study of diffusion of Augmentin in middle ear in a population of children with chronic serous otitis media requiring transtympanic drains. Three day course of Augmentin (80 mg/kg/j three times a day, formula 100mg/ml) prior to the planned surgery.
25000/546 Completed A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Oral Augmentin SR 2000/125mg Twice Daily Versus Oral Augmentin 875/125mg Twice Daily for 7 Days in the Treatment of Adults with Bacterial Community Acquired Pneumonia

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.